<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4718">
  <stage>Registered</stage>
  <submitdate>5/03/2012</submitdate>
  <approvaldate>5/03/2012</approvaldate>
  <nctid>NCT01548352</nctid>
  <trial_identification>
    <studytitle>BAsel Syncope EvaLuation (BASEL IX) Study</studytitle>
    <scientifictitle>BAsel Syncope EvaLuation (BASEL IX) Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BASEL IX</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Syncope</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>diagnostic and prognostic value of various novel and established biomarkers, clinical assessment and detailed patient history</outcome>
      <timepoint>within 24 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients presenting to the emergency department

          -  Age &gt; 40 years

          -  Syncope within the last 12 hours

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Age &lt; 40 years

          -  Patients without loss of consciousness and with certain neurological causes (e.g.
             recurrent epilepsy, hemiplegia at presentation)

          -  No written informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>720</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Brisbane and Women's hospital - Brisbane</hospital>
    <postcode>QLD 4029 - Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Zabrze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Baselland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Schwyz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zurich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University Hospital, Basel, Switzerland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Swiss National Science Foundation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Syncope is a major health problem. In the emergency department (ED), the management of
      patients with syncope still remains a clinical challenge because underlying diseases and
      prognosis can be extremely various. Structural heart disease and primary electrical disorders
      are major risk factors for sudden cardiac death and mortality in patients with syncope. In
      contrast, patients with reflex syncope and exclusion of structural heart disease have an
      excellent prognosis.

      Therefore The investigators test the hypothesis that the use of a meticulous patient history,
      clinical examination and novel biomarkers can improve the rapid and accurate diagnosis of
      cardiac syncope in patients presenting to the ED and is able to improve risk stratification
      regarding adverse outcomes.

      The prospective multicenter cohort study is designed to enroll 720 patients presenting with
      transient loss of consciousness within the last 12 hours to the ED. Blood samples for the
      measurement of novel biomarkers will be obtained at presentation.

      All patients will be contacted by phone at 6, 12 and 24 months to determine major adverse
      events (death, resuscitation, recurrence of syncope, hospitalization for syncope).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01548352</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Christian Mueller, MD</name>
      <address>University Hospital, Basel, Switzerland</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Christian Mueller, MD</name>
      <address />
      <phone>0041-61-2652525</phone>
      <fax />
      <email>christian.mueller@usb.ch</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>